Veeva Systems Inc. (VEEV) has an unusually tidy knot at the center of its relationship map: Salesforce (CRM) supplies the platform behind Veeva CRM, competes with Veeva in life-sciences software, and has partnered with Veeva competitor IQVIA (IQV). The supplier is not merely in the vendor list. It is also building a competing product.
Veeva’s March 2026 filing spells out the plumbing behind that connection:
"Cost of subscription revenues for Veeva CRM and certain of our multichannel customer relationship management applications include fees paid to Salesforce. for our use of the Salesforce platform and the associated hosting infrastructure and data center…"
Veeva / 10-K / March 20, 2026
In plain English, Salesforce platform and infrastructure fees sit inside the cost of delivering parts of Veeva’s CRM business. Veeva names Salesforce as its supplier for that piece of the stack.
The older disclosure adds a strategic wrinkle. Veeva says it has started moving customers from that Salesforce-backed product to its own platform:
"We currently depend on the Salesforce platform to deliver our Veeva CRM application, but we have begun to migrate our CRM customers to our Vault CRM solutions, which are built on our Veeva Vault platform."
Veeva / 10-K / June 2, 2025
That makes the relationship both current and transitional in Veeva’s own telling. Veeva CRM depends on Salesforce, while Vault CRM is the company’s stated migration path away from that platform.
Salesforce is not standing still on the other side of the relationship. Veeva disclosed that Salesforce is developing a life-sciences CRM application, and that it has joined forces with IQVIA:
"For example, Salesforce, Inc. is developing a life sciences industry-specific CRM application that will compete with our offerings and has entered into a partnership with IQVIA."
Veeva / 10-K / June 2, 2025
IQVIA therefore appears twice in the map: Veeva identifies it as a competitor, and Veeva also identifies its partnership with Salesforce. IQVIA’s own February 2026 filing names Veeva as a competitor. One company is supplying Veeva, while its partner is also a named rival. Corporate relationships do enjoy a little dramatic irony.
Veeva’s customer side is more pharmaceutical than platform. Its filing names Eli Lilly and Company (LLY), Gilead Sciences, Inc. (GILD), Merck & Company, Inc. (MRK), Alkermes plc (ALKS), and Alnylam Pharmaceuticals, Inc. (ALNY), alongside other large drugmakers:
"Our life sciences customers range from the largest global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging…"
Veeva / 10-K / March 20, 2026
The disclosure places Veeva inside the software budgets of both global pharmaceutical companies and emerging biotech businesses. It does not assign revenue percentages to the named customers, so the filing provides a customer roster, not a concentration figure.
Beyond CRM, Veeva names Oracle (ORCL) and Honeywell International Inc. (HON) among the companies offering competing solutions across parts of its Development Cloud and Quality Cloud business:
"No single vendor offers products that compete with all of our Veeva Development Cloud or Quality Cloud applications, but IQVIA, Dassault Systèmes, OpenText Corporation, Oracle Corporation, Honeywell International Inc., and other smaller application providers…"
Veeva / 10-K / June 5, 2026
Microsoft Corporation (MSFT) is also named among competitors in a separate disclosure.
The map is lopsided in a specific way: one disclosed platform supplier, a migration toward Veeva’s own platform, a customer base of drugmakers, and a competitive field that includes the supplier itself. Veeva’s filings disclose the relationships. They do not turn the web into a forecast.
These are relationships disclosed in SEC filings, mapped by jodie’s analytics. This is not investment advice.